ResMed | RMD - Cost Of Sales


ResMed reported $551.67M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Ansell USD 605.3M 351.2M Dec/2025
Artivion USD 42.85M 3.86M Dec/2025
AtriCure USD 31.94M 3.22M Mar/2026
Baxter International USD 1.81B 587M Mar/2026
Cochlear AUD 319.2M 160.35M Dec/2025
Cooper Companies USD 393.8M 17M Mar/2026
CSL USD 3.87B 2.08B Dec/2025
Dexcom USD 441.6M 25.3M Mar/2026
Edwards Lifesciences USD 362.6M 19.6M Mar/2026
Fisher Paykel Healthcare NZD 402.8M 15.2M Dec/2025
Globus Medical USD 263.59M 26.88M Mar/2026
Haemonetics USD 136.58M 4.01M Dec/2025
Idexx Laboratories USD 418.08M 14.38M Mar/2026
Inogen USD 39.59M 1.27M Sep/2024
Insulet USD 232.7M 17.5M Mar/2026
Integra LifeSciences USD 178.71M 14.73M Mar/2026
Intuitive Surgical USD 940.3M 21.6M Mar/2026
Medtronic USD 3.8B 195M Mar/2026
Philips EUR 2.14B 669M Mar/2026
Ramsay Health Care AUD 3.05B 78.7M Dec/2025
ResMed USD 551.67M 4.17M Mar/2026
Sigma Healthcare AUD 1.55B 165.16M Dec/2024
Sonic Healthcare AUD 751.66M 801.13M Dec/2024
Steris USD 891.3M 50.6M Mar/2026
Teleflex USD 240.84M 20.7M Mar/2026
Thermo Fisher Scientific USD 6.96B 620M Mar/2026